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Background 
The ICON7 trial reported increased progression-free survival with bevacizumab (bev) added to 
platinum-based chemotherapy in newly-diagnosed ovarian cancer, and increased overall survival 
(OS) in a poor prognosis subset. Most patients (pts) had further chemotherapy following 
progression. On average, pts receiving bev had later progression and were thus more likely to 
receive further platinum. We investigated the effect of second-line treatment type on the 
association between first-line bev and OS.  
Methods   
Second line chemotherapy regimens were categorised as platinum-containing or other. Platinum 
reuse varied with time to progression after end of 1st line (excl. maintenance bev) and also varied 
between centres. We categorised centres as high or low platinum use, from the proportion of their 
pts progressing in 0-8 months (mths) and retreated with platinum. The association between 1st line 
bev and OS was analysed separately at low-use centres and at high-use centres. Standard survival 
analysis techniques and methods appropriate for data with non-proportional hazards were used. 
Results   
ICON7 randomised 1528 pts 1:1 to reference treatment +/- bev. Reference pts were more likely to 
experience disease progression ≤8 mths (38% v 24%). Reuse of platinum varied with time to 
progression; 37% at 0-5 mths; 76% at 6-8 mths; 94% at ≥9 mths. 174 centres (covering 1290 pts) had 
≥1 progressions at 0-8 mths, 76 centres were classed low-use (<50% platinum 2nd line in 0-8mths) 
and 98 high-use. 
The earlier progression of reference pts resulted in fewer getting 2nd line platinum at low use centres 
(41% v 56%), but not at high-use centres (76% v 77%). There was evidence of significantly shorter OS 
among reference pts at low-use centres (p=0.05, restricted mean survival 44.1 v 49.0 mths), but not 
at high-use centres (p=0.20, restricted mean survival 52.2 v 50.0 mths).  
Conclusion   
Improved OS with bevacizumab may result from an association with platinum-containing second line 
treatment: bev increases time to progression, increased time to progression increases the likelihood 
of second line platinum, second line platinum increases OS. It is possible therefore that OS might be 
improved by a lower time threshold for second line platinum chemotherapy, whether or not 
bevacizumab has been used. 
